Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| University of Oklahoma | OTHER |
Not provided
Not provided
Not provided
Not provided
Many hospitals and outpatient clinics often refer people who smoke to quitlines and provide prescriptions for smoking cessation medications, but patients rarely fully engage in counseling or use their cessation medications. This is a single-arm, open-label pilot study to provide feasibility metrics for a text-based contingency management (CM) intervention to increase engagement in smoking cessation treatment. All participants (N=20) will be referred to a state quitline and will receive a prescription for medication plus 12 weeks of a text-based CM intervention to increase engagement in quitline calls and varenicline utilization. The engagement of participants in quitline counseling will be tracked for 6 weeks and medication utilization for 12 weeks post-enrollment. The investigators will use mixed-methods to collect implementation and acceptability data to inform changes to the text-based contingency management (CM) intervention.
Novel approaches are needed to engage people who smoke in treatment in a way that increases their odds of quitting. Contingency management (CM) interventions provide financial incentives to participants contingent on objective evidence of behavior change and are effective in enhancing medication adherence and treatment engagement for numerous health conditions, including tobacco dependence treatment. Critical gaps, however, remain in our knowledge regarding how best to deploy CM.
The goal of this study is to evaluate the acceptability and feasibility of combined CM for engaging patients in smoking cessation treatment. Participants (N=20) will receive "CounsCM" for engaging in five quitline calls and "MedCM" for utilizing varenicline over twelve weeks. CM payments will be automated and dispensed on a daily basis using a reloadable debit card. The investigators will use surveys and structured interviews to understand strengths, weaknesses, and areas for improvement.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MedCM plus CounsCM | Experimental | Mobile Contingency Management for counseling attendance and medication intake |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CounsCM+MedCM (Health Rewards) | Behavioral | Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of quitline calls completed | Completion of the five quitline calls over 6 weeks of treatment according to Kansas quitline reports | Week 6 |
| Proportion of varenicline pills taken | Varenicline intake over 12 weeks of treatment according to the smart pill dispenser counting | Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients adherent to varenicline | Adherence biochemically verified using saliva samples, 1.0 ng/ml as the cutoff to distinguish between participants adherent and adherent | Week 3 |
| Proportion of self-reported varenicline pills taken |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | 66103 | United States |
Not provided
| ID | Term |
|---|---|
| D016540 | Smoking Cessation |
| ID | Term |
|---|---|
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Self-reported use of varenicline from a timeline followback questionnaire assessing varenicline pills taken in each of the past 3 days
| Week 3 |
| Proportion of patients with biochemically verified smoking abstinence | Biochemically confirmed 7-day point prevalence abstinence using the anabasine criteria cutoff of ≤ 2 ng/ml | Week 12 |
| Proportion of patients with self-reported smoking abstinence | Past 7 days self-reported smoking abstinence | Week 12 |